Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:PGNX
- CUSIP: 74318710
- Web: www.progenics.com
Capitalization:- Market Cap: $488.37 million
- Outstanding Shares: 70,269,000
Average Prices:- 50 Day Moving Avg: $6.01
- 200 Day Moving Avg: $7.45
- 52 Week Range: $4.60 - $11.72
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.31
- P/E Growth: -0.02
Sales & Book Value:- Annual Revenue: $63.62 million
- Price / Sales: 7.68
- Book Value: $1.06 per share
- Price / Book: 6.56
Profitability:- EBIDTA: ($958,000.00)
- Net Margins: -6.13%
- Return on Equity: -4.11%
- Return on Assets: -2.20%
Debt:- Debt-to-Equity Ratio: 0.65%
- Current Ratio: 7.28%
- Quick Ratio: 7.28%
Misc:- Average Volume: 1.03 million shs.
- Beta: 3.4
- Short Ratio: 12.56
Frequently Asked Questions for Progenics Pharmaceuticals (NASDAQ:PGNX)
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) issued its earnings results on Wednesday, August, 9th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The firm earned $2.77 million during the quarter, compared to analysts' expectations of $3.34 million. Progenics Pharmaceuticals had a negative net margin of 6.13% and a negative return on equity of 4.11%. The business's revenue for the quarter was down 67.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.08) EPS. View Progenics Pharmaceuticals' Earnings History.
When will Progenics Pharmaceuticals make its next earnings announcement?
Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2017?
6 analysts have issued 1 year target prices for Progenics Pharmaceuticals' shares. Their forecasts range from $11.00 to $15.00. On average, they anticipate Progenics Pharmaceuticals' share price to reach $12.83 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.
What are analysts saying about Progenics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "NDA Submission for Azedra this Month. PGNX has completed a pre- submission meeting for Azedra with the FDA and an NDA submission should follow this month. The drug has been awarded Breakthrough designation and was developed under a SPA. Top line results were released earlier this year and a fuller data set is expected to be presented at the International Symposium of Pheochromocytoma and Paraganglioma on September 1." (8/9/2017)
- 2. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (7/5/2017)
- 3. Needham & Company LLC analysts commented, "We recently chose PGNX as our Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. We continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Our increased $14 price target reflects the introduction of estimates for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial." (2/6/2017)
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Ascendis Pharma A/S (ASND), Omeros Corporation (OMER), REGENXBIO (RGNX), Amarin Corporation PLC (AMRN), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), ZIOPHARM Oncology (ZIOP), PTC Therapeutics (PTCT), Keryx Biopharmaceuticals (KERX), Vanda Pharmaceuticals (VNDA), Flexion Therapeutics (FLXN), Aduro Biotech (ADRO), Reata Pharmaceuticals (RETA), Versartis (VSAR), Adaptimmune Therapeutics PLC (ADAP), La Jolla Pharmaceutical Company (LJPC), Cytokinetics, Incorporated (CYTK) and Revance Therapeutics (RVNC).
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Peter J. Crowley, Independent Chairman of the Board
- Mark R. Baker J.D., Chief Executive Officer, Director
- Patrick Fabbio, Chief Financial Officer
- Nitya G. Ray Ph.D., Senior Vice President - Manufacturing
- Vivien Wong Ph.D., Senior Vice President - Operations and Portfolio Management
- Ann Marie Assumma, Vice President - Regulatory Affairs
- Karen Jean Ferrante M.D., Independent Director
- Michael D. Kishbauch, Independent Director
- David A. Scheinberg MD., Ph.D., Independent Director
- Nicole S. Williams, Independent Director
Who owns Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (15.54%), Vanguard Group Inc. (6.12%), Eagle Asset Management Inc. (5.71%), State Street Corp (5.28%), FMR LLC (3.80%) and Pinnacle Associates Ltd. (3.50%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Who sold Progenics Pharmaceuticals stock? Who is selling Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Broadfin Capital LLC, Goldman Sachs Group Inc., Gotham Asset Management LLC, FMR LLC, Russell Investments Group Ltd., Alliancebernstein L.P. and Pinnacle Associates Ltd.. View Insider Buying and Selling for Progenics Pharmaceuticals.
Who bought Progenics Pharmaceuticals stock? Who is buying Progenics Pharmaceuticals stock?
Progenics Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., State Street Corp, Numeric Investors LLC, Rice Hall James & Associates LLC, ING Groep NV, Vanguard Group Inc., Marshall Wace North America L.P. and GSA Capital Partners LLP. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy Progenics Pharmaceuticals stock?
Shares of Progenics Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of Progenics Pharmaceuticals stock can currently be purchased for approximately $6.95.
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Progenics Pharmaceuticals (NASDAQ:PGNX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.17) |
| Consensus Price Target: | $12.83 (84.65% upside) |
Analysts' Ratings History for Progenics Pharmaceuticals (NASDAQ:PGNX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/5/2017 | Cantor Fitzgerald | Reiterated Rating | Overweight | $15.00 | Low |  |
| 9/1/2017 | Needham & Company LLC | Reiterated Rating | Strong-Buy | $14.00 | Medium | |
| 8/22/2017 | Aegis | Reiterated Rating | Buy | $14.00 | Low | |
| 6/8/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $12.00 | High | |
| 11/30/2016 | BTIG Research | Boost Price Target | Buy | $9.00 -> $11.00 | N/A | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $11.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Progenics Pharmaceuticals (NASDAQ:PGNX)Earnings History by Quarter for Progenics Pharmaceuticals (NASDAQ PGNX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.23) | | | | | N/A | |
| 8/9/2017 | Q2 2017 | ($0.20) | ($0.24) | $3.34 million | $2.77 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.16) | ($0.23) | $4.50 million | $2.40 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.20) | ($0.10) | $4.43 million | $4.65 million | View | Listen | |
| 11/7/2016 | Q316 | $0.55 | $0.52 | $52.90 million | $53.90 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.13) | ($0.08) | $6.33 million | $8.50 million | View | N/A | |
| 5/5/2016 | Q116 | ($0.13) | ($0.18) | $3.27 million | $2.50 million | View | Listen | |
| 3/11/2016 | Q415 | ($0.14) | ($0.10) | $2.25 million | $5.10 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.13) | ($0.14) | $2.35 million | $1.40 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.15) | ($0.17) | $1.63 million | $1.90 million | View | Listen | |
| 5/6/2015 | Q115 | ($0.16) | ($0.15) | $1.30 million | $0.25 million | View | N/A | |
| 3/16/2015 | Q414 | ($0.13) | ($0.18) | $2.87 million | ($0.57) million | View | N/A | |
| 11/7/2014 | Q314 | ($0.16) | $0.51 | $2.50 million | $41.66 million | View | N/A | |
| 8/8/2014 | Q214 | ($0.14) | ($0.17) | $2.83 million | $1.50 million | View | Listen | |
| 5/9/2014 | Q114 | ($0.15) | ($0.15) | $2.88 million | $1.80 million | View | N/A | |
| 3/13/2014 | Q4 | ($0.19) | ($0.14) | $1.48 million | $3.00 million | View | Listen | |
| 11/11/2013 | Q313 | ($0.22) | ($0.17) | $2.00 million | $0.90 million | View | N/A | |
| 8/9/2013 | Q2 2013 | ($0.24) | ($0.24) | $1.86 million | $1.80 million | View | N/A | |
| 5/10/2013 | Q1 2013 | ($0.19) | ($0.22) | $1.71 million | $2.23 million | View | N/A | |
| 3/15/2013 | Q4 2012 | ($0.31) | ($0.01) | $1.16 million | $8.87 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.30) | ($0.33) | $2.52 million | $1.10 million | View | N/A | |
| 8/9/2012 | | ($0.32) | ($0.32) | | | View | N/A | |
| 5/8/2012 | | ($0.33) | ($0.39) | | | View | N/A | |
| 11/9/2011 | | ($0.33) | ($0.34) | | | View | N/A | |
| 8/9/2011 | | ($0.25) | $1.64 | | | View | N/A | |
| 5/10/2011 | | ($0.51) | ($0.69) | | | View | N/A | |
| 3/15/2011 | | ($0.57) | ($0.57) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Progenics Pharmaceuticals (NASDAQ:PGNX)2017 EPS Consensus Estimate: ($0.61)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.16) | ($0.16) | ($0.16) |
| Q2 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q3 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
| Q4 2017 | 1 | ($0.15) | ($0.15) | ($0.15) |
(Data provided by Zacks Investment Research)
Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Progenics Pharmaceuticals (NASDAQ:PGNX)Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 89.17%
Insider Trades by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/15/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 602,600 | $9.66 | $5,821,116.00 | |
| 2/9/2017 | Healthcare Master Fun Broadfin | Major Shareholder | Sell | 351,300 | $9.71 | $3,411,123.00 | |
| 6/11/2015 | Robert J Israel | EVP | Sell | 2,000 | $6.83 | $13,660.00 | |
| 3/13/2015 | Robert J Israel | EVP | Sell | 3,000 | $7.00 | $21,000.00 | |
| 3/11/2015 | Robert J Israel | EVP | Sell | 2,000 | $6.83 | $13,660.00 | |
| 3/3/2015 | Robert J Israel | EVP | Sell | 5,000 | $6.49 | $32,450.00 | |
| 1/12/2015 | Robert J Israel | EVP | Sell | 2,000 | $7.06 | $14,120.00 | |
| 12/11/2014 | Robert J Israel | EVP | Sell | 3,000 | $7.07 | $21,210.00 | |
| 11/21/2014 | Robert J Israel | EVP | Sell | 9,000 | $7.00 | $63,000.00 | |
| 11/13/2014 | Robert J Israel | EVP | Sell | 10,000 | $6.83 | $68,300.00 | |
| 11/11/2014 | Robert J Israel | EVP | Sell | 5,000 | $6.53 | $32,650.00 | |
| 7/21/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 1,625,436 | $4.60 | $7,477,005.60 | |
| 7/18/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 388,200 | $4.73 | $1,836,186.00 | |
| 7/17/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 436,884 | $4.48 | $1,957,240.32 | |
| 7/16/2014 | Healthcare Master Fun Broadfin | Major Shareholder | Buy | 411,693 | $4.48 | $1,844,384.64 | |
| 7/18/2013 | Robert J Israel | VP | Sell | 5,000 | $6.33 | $31,650.00 | |
| 2/27/2013 | Mark Robert Baker | CEO | Buy | 1,262 | $2.72 | $3,432.64 | |
| 1/22/2013 | Mark Robert Baker | CEO | Buy | 1,215 | $2.82 | $3,426.30 | |
| 12/26/2012 | Mark Robert Baker | CEO | Buy | 1,142 | $3.01 | $3,437.42 | |
| 11/28/2012 | Mark Robert Baker | CEO | Buy | 1,607 | $2.13 | $3,422.91 | |
| 11/19/2012 | Mark Robert Baker | CEO | Buy | 11,800 | $1.96 | $23,128.00 | |
| 11/16/2012 | Mark Robert Baker | CEO | Buy | 49,793 | $1.82 | $90,623.26 | |
| 11/15/2012 | Mark Robert Baker | CEO | Buy | 48,833 | $1.69 | $82,527.77 | |
| 10/24/2012 | Mark Robert Baker | CEO | Buy | 1,162 | $2.96 | $3,439.52 | |
| 9/26/2012 | Mark Robert Baker | CEO | Buy | 1,036 | $3.32 | $3,439.52 | |
(Data available from 1/1/2013 forward)
Headline Trends for Progenics Pharmaceuticals (NASDAQ:PGNX)
Latest Headlines for Progenics Pharmaceuticals (NASDAQ:PGNX)
| Source: |
|
| Date | Headline |
|---|
 | What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
finance.yahoo.com - September 19 at 6:29 AM |
 | What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
www.fool.com - September 18 at 2:08 PM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 15 at 7:34 AM |
| Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 9:13 AM |
| Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : September 12, 2017
finance.yahoo.com - September 13 at 7:45 AM |
 | Progenics: Draining The Azedra Quagmire - Seeking Alpha
seekingalpha.com - September 9 at 7:20 AM |
 | Progenics Pharmaceuticals Inc. (PGNX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 6 at 4:46 AM |
| Progenics's Azedra: What's Wrong With This Picture? - Seeking Alpha
seekingalpha.com - September 5 at 10:26 PM |
| What Would Progenics Be Worth Without Azedra? - Seeking Alpha - Seeking Alpha
seekingalpha.com - September 5 at 10:26 PM |
| Cantor Fitzgerald Reaffirms "Overweight" Rating for Progenics Pharmaceuticals Inc. (PGNX)
www.americanbankingnews.com - September 5 at 9:42 AM |
| Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA®
finance.yahoo.com - September 2 at 7:29 AM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharmaceuticals Inc. - PGNX
finance.yahoo.com - September 2 at 7:29 AM |
| Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 2, 2017
finance.yahoo.com - September 2 at 7:29 AM |
| Progenics Pharmaceuticals' (PGNX) "Strong-Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - September 1 at 12:56 PM |
 | Progenics Pharma (PGNX) Reports Update on Timing of NDA Submission for AZEDRA - StreetInsider.com
www.streetinsider.com - September 1 at 7:12 AM |
| Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : August 30, 2017
finance.yahoo.com - August 31 at 8:41 AM |
| Progenics Pharmaceuticals, Inc.: Gathering momentum, can it sustain its performance?
finance.yahoo.com - August 30 at 7:56 AM |
| A Key Week Ahead For Progenics Pharmaceuticals - Seeking Alpha
seekingalpha.com - August 29 at 6:39 AM |
| Progenics' AZEDRA: A Minority Report - Seeking Alpha
seekingalpha.com - August 26 at 8:17 AM |
| Progenics: Unloved And Undervalued ~$5 Biotech Stock - Seeking Alpha
seekingalpha.com - August 13 at 8:04 PM |
| Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 12 at 4:32 AM |
| Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update
finance.yahoo.com - August 10 at 6:50 AM |
| Edited Transcript of PGNX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 6:50 AM |
| Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
finance.yahoo.com - August 10 at 6:50 AM |
| Progenics reports 2Q loss
finance.yahoo.com - August 10 at 6:50 AM |
| Progenics Pharmaceuticals Inc. (PGNX) Posts Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - August 9 at 5:22 PM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 6:57 AM |
| Progenics Pharmaceuticals Inc. (PGNX) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - August 4 at 12:22 AM |
| Progenics Pharmaceuticals Inc. (PGNX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:32 AM |
| Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9
finance.yahoo.com - July 27 at 6:20 AM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:56 PM |
| Progenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 2:45 PM |
| Biotech Forum Daily Digest: Why Progenics Could Rally This Summer - Seeking Alpha
seekingalpha.com - July 18 at 7:18 AM |
| Progenics Pharmaceuticals Inc. to Post FY2017 Earnings of ($0.99) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:PGNX)
www.americanbankingnews.com - July 17 at 8:53 AM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 7:29 AM |
| Progenics Shares Could Double, According To Cantor
finance.yahoo.com - July 13 at 7:55 AM |
| Progenics Pharmaceuticals Inc. (PGNX) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 5 at 8:36 AM |
| Progenics Pharmaceuticals Inc. (PGNX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 23 at 11:47 AM |
| Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US : June 22, 2017
finance.yahoo.com - June 23 at 9:03 AM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 9:03 AM |
| ETFs with exposure to Progenics Pharmaceuticals, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:51 PM |
| Progenics Pharmaceuticals (PGNX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 7:24 PM |
| Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 7:24 PM |
| Progenics Pharmaceuticals' (PGNX) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 8 at 9:10 PM |
| Zacks Investment Research Upgrades Progenics Pharmaceuticals, Inc. (PGNX) to "Hold"
www.americanbankingnews.com - June 6 at 7:06 AM |
| Progenics Pharma (PGNX) Announces Presentation of Data From Two Automated Bone Scan Index Studies at ASCO
www.streetinsider.com - June 3 at 2:44 AM |
| Progenics Pharma (PGNX) Announces Presentation of Data From Two Automated Bone Scan Index Studies at ASCO - StreetInsider.com
www.streetinsider.com - June 2 at 9:43 PM |
| Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Studies at the 2017 ASCO Annual Meeting
finance.yahoo.com - June 2 at 9:43 PM |
 | Progenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference - Nasdaq
www.nasdaq.com - June 1 at 8:03 PM |
| TheStreet Lowers Progenics Pharmaceuticals, Inc. (PGNX) to D+
www.americanbankingnews.com - June 1 at 2:22 PM |
Progenics Pharmaceuticals (PGNX) Chart for Thursday, September, 21, 2017
